Gilead Sciences offers innovative drugs and boasts a 45,000% return since IPO, highlighting substantial growth. Investing in Gilead is accessible via brokerage accounts, using simple steps to buy ...

While the broader market has struggled with the S&P 500 down 2.4% since December 2024, Gilead Sciences has surged ahead as its stock price has climbed by 21% to $111.47 per share. This performance may ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. Featuring daily updates ...

Last week, biotech bigwig Gilead Sciences, Inc. GILD reported lower-than-expected first-quarter 2025 results. Adjusted earnings per share (EPS) of $1.81 missed the Zacks Consensus Estimate by a penny.

Thanks for joining us. I’m Tim Anderson, the U.S. large cap pharma and biotech analyst of Bank of America and excited to have Gilead with us today, specifically Johanna Mercier, who serves as the ...

Gilead Sciences GILD recently announced that it has exercised its combined option to exclusively license Assembly Biosciences ...

Generally speaking, I’m not a big fan of discussing biopharmaceutical firms such as Gilead Sciences (NASDAQ:GILD). While the sector is intriguing and offers bountiful opportunities, it’s also replete ...

During market trading hours on Wednesday, the U.S. Food and Drug Administration (FDA) approved Gilead Sciences, Inc.’s (NASDAQ:GILD) Yeztugo (lenacapavir) as pre-exposure prophylaxis (PrEP) to reduce ...